A detailed history of Profund Advisors LLC transactions in Xencor Inc stock. As of the latest transaction made, Profund Advisors LLC holds 15,320 shares of XNCR stock, worth $369,671. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,320
Previous 20,036 23.54%
Holding current value
$369,671
Previous $379,000 18.73%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.7 - $21.65 $74,041 - $102,101
-4,716 Reduced 23.54%
15,320 $308,000
Q2 2024

Aug 13, 2024

SELL
$18.21 - $24.5 $328,417 - $441,857
-18,035 Reduced 47.37%
20,036 $379,000
Q1 2024

May 08, 2024

BUY
$18.65 - $26.52 $286,128 - $406,869
15,342 Added 67.5%
38,071 $842,000
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $19,637 - $25,446
1,188 Added 5.52%
22,729 $482,000
Q3 2023

Nov 13, 2023

SELL
$20.08 - $25.39 $62,348 - $78,835
-3,105 Reduced 12.6%
21,541 $434,000
Q2 2023

Aug 10, 2023

SELL
$24.77 - $29.9 $47,855 - $57,766
-1,932 Reduced 7.27%
24,646 $615,000
Q1 2023

May 11, 2023

BUY
$25.95 - $36.95 $689,699 - $982,057
26,578 New
26,578 $741,000
Q1 2022

May 10, 2022

SELL
$26.68 - $41.63 $141,964 - $221,513
-5,321 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$33.67 - $43.44 $179,158 - $231,144
5,321 New
5,321 $213,000
Q3 2021

Nov 12, 2021

SELL
$30.65 - $35.68 $193,033 - $224,712
-6,298 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$34.33 - $44.68 $8,204 - $10,678
239 Added 3.94%
6,298 $217,000
Q1 2021

May 14, 2021

SELL
$40.81 - $53.88 $26,322 - $34,752
-645 Reduced 9.62%
6,059 $261,000
Q4 2020

Feb 09, 2021

BUY
$36.63 - $47.63 $245,567 - $319,311
6,704 New
6,704 $292,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.44B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.